320 related articles for article (PubMed ID: 27139468)
1. Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae.
Albiero J; Sy SK; Mazucheli J; Caparroz-Assef SM; Costa BB; Alves JL; Gales AC; Tognim MC
Antimicrob Agents Chemother; 2016 Jul; 60(7):4128-39. PubMed ID: 27139468
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase.
Albiero J; Mazucheli J; Barros JPDR; Szczerepa MMDA; Nishiyama SAB; Carrara-Marroni FE; Sy S; Fidler M; Sy SKB; Tognim MCB
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910903
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
Bulik CC; Christensen H; Li P; Sutherland CA; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2010 Feb; 54(2):804-10. PubMed ID: 19995927
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae.
Cojutti P; Sartor A; Righi E; Scarparo C; Bassetti M; Pea F
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760900
[TBL] [Abstract][Full Text] [Related]
5. Polymyxin B in Combination with Rifampin and Meropenem against Polymyxin B-Resistant KPC-Producing Klebsiella pneumoniae.
Diep JK; Jacobs DM; Sharma R; Covelli J; Bowers DR; Russo TA; Rao GG
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872078
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Activity and Emergence of Resistance of Polymyxin B and ZTI-01 (Fosfomycin for Injection) against KPC-Producing Klebsiella pneumoniae.
Diep JK; Sharma R; Ellis-Grosse EJ; Abboud CS; Rao GG
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203494
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-pharmacodynamic modelling of meropenem against VIM-producing Klebsiella pneumoniae isolates: clinical implications.
Tsala M; Vourli S; Kotsakis S; Daikos GL; Tzouvelekis L; Zerva L; Miriagou V; Meletiadis J
J Med Microbiol; 2016 Mar; 65(3):211-218. PubMed ID: 26697851
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains.
Evren E; Azap OK; Çolakoğlu Ş; Arslan H
Diagn Microbiol Infect Dis; 2013 Jul; 76(3):335-8. PubMed ID: 23726147
[TBL] [Abstract][Full Text] [Related]
10. Strategies for the treatment of polymyxin B-resistant Acinetobacter baumannii infections.
Menegucci TC; Albiero J; Migliorini LB; Alves JL; Viana GF; Mazucheli J; Carrara-Marroni FE; Cardoso CL; Tognim MC
Int J Antimicrob Agents; 2016 May; 47(5):380-5. PubMed ID: 27068675
[TBL] [Abstract][Full Text] [Related]
11. Polymyxin B and fosfomycin thwart KPC-producing Klebsiella pneumoniae in the hollow-fibre infection model.
Bulman ZP; Zhao M; Satlin MJ; Chen L; Kreiswirth BN; Walsh TJ; Nation RL; Li J; Tsuji BT
Int J Antimicrob Agents; 2018 Jul; 52(1):114-118. PubMed ID: 29486233
[TBL] [Abstract][Full Text] [Related]
12. In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development.
Souli M; Galani I; Boukovalas S; Gourgoulis MG; Chryssouli Z; Kanellakopoulou K; Panagea T; Giamarellou H
Antimicrob Agents Chemother; 2011 May; 55(5):2395-7. PubMed ID: 21321144
[TBL] [Abstract][Full Text] [Related]
13. Optimal empiric treatment for KPC-2-producing Klebsiella pneumoniae infections in critically ill patients with normal or decreased renal function using Monte Carlo simulation.
Wang G; Yu W; Cui Y; Shi Q; Huang C; Xiao Y
BMC Infect Dis; 2021 Mar; 21(1):307. PubMed ID: 33771113
[TBL] [Abstract][Full Text] [Related]
14. Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae.
Sun D; Rubio-Aparicio D; Nelson K; Dudley MN; Lomovskaya O
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 29038260
[TBL] [Abstract][Full Text] [Related]
15. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
DeRyke CA; Banevicius MA; Fan HW; Nicolau DP
Antimicrob Agents Chemother; 2007 Apr; 51(4):1481-6. PubMed ID: 17283197
[TBL] [Abstract][Full Text] [Related]
16. Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem plus fosfomycin in paediatrics.
Martins FS; Zhu P; Heinrichs MT; Sy SKB
Br J Clin Pharmacol; 2021 Mar; 87(3):1012-1023. PubMed ID: 32638408
[TBL] [Abstract][Full Text] [Related]
17. In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase.
Wiskirchen DE; Koomanachai P; Nicasio AM; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2011 Apr; 55(4):1420-7. PubMed ID: 21282442
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia.
Jaruratanasirikul S; Limapichat T; Jullangkoon M; Aeinlang N; Ingviya N; Wongpoowarak W
Int J Antimicrob Agents; 2011 Sep; 38(3):231-6. PubMed ID: 21726984
[TBL] [Abstract][Full Text] [Related]
19. Modeling Meropenem Treatment, Alone and in Combination with Daptomycin, for KPC-Producing Klebsiella pneumoniae Strains with Unusually Low Carbapenem MICs.
Gagetti P; Pasteran F; Martinez MP; Fatouraei M; Gu J; Fernandez R; Paz L; Rose WE; Corso A; Rosato AE
Antimicrob Agents Chemother; 2016 Aug; 60(8):5047-50. PubMed ID: 27216067
[TBL] [Abstract][Full Text] [Related]
20.
Huang D; Yu B; Diep JK; Sharma R; Dudley M; Monteiro J; Kaye KS; Pogue JM; Abboud CS; Rao GG
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
